In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Cardiovascular magnetic resonance (CMR) predictors of clinical outcomes in patients with hypertrophic cardiomyopathy

Session Poster session 1

Speaker Bhishma Chowdary Donepudi

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Late Gadolinium Enhancement and Viability
  • Session type : Poster Session
  • FP Number : P166

Authors : BC Donepudi (Kochi,IN), R Thachathodiyl (Kochi,IN)

Authors:
BC Donepudi1 , R Thachathodiyl1 , 1Amrita Institute of Medical Sciences (AIMS) - Kochi - India ,

Citation:
European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii122

Background: Hypertrophic cardiomyopathy (HCM), the most common genetic cardiomyopathy, is a disease characterized by substantial heterogeneity. Cardiovascular magnetic resonance (CMR) with late gadolinium enhancement (LGE) has the capability to identify areas of myocardial fibrosis/scarring with novel data demonstrating that the extent of LGE by CMR may play an important role in risk stratification of patients with HCM.

Purpose: The purpose of this study was to determine the prognostic significance of cardiac magnetic resonance (CMR) findings in patients with hypertrophic cardiomyopathy (HCM).

Materials and Methods: Cardiac MRI studies of 67 patients with HCM were retrospectively evaluated. Quantification of late gadolinium enhancement (LGE) was determined and expressed as a percentage of total left ventricular (LV) myocardial mass (%LGE). Morphologic features including the presence of an apical aneurysm, IVS thickness and LV thrombus were also assessed. Clinical data were collected during follow-up to assess for the occurrence of major adverse events, defined as heart failure, stroke, sustained ventricular tachycardia, aborted sudden cardiac death, and/or all-cause death.

Results: The mean age of the patients was 48.22±14.7years, and 71.6% (n= 48) were males with mean ESC SCD risk score of 3.12±2.56. The mean Left ventricular EF was 59.3±8.6%, mean IVS thickness was 2.40±6.1, 10.4% had an AICD, 9.0% underwent Septal myectomy, 4.5% underwent Alcohol septal ablation. LGE, Apical aneurysm, and LV thrombus were identified in 76.1%, 4.5%, 3% respectively. Mean %LGE was 14.94%± 12.05%. Over 2.4± 1.7 years of follow-up, 15 subjects (22.4%) experienced a major adverse event, heart failure (11.9%), stroke (3%) sustained ventricular tachycardia (3%), aborted sudden cardiac death (3%), and all-cause death (1.5%). Presence of extent of LGE and apical aneurysm were significant predictors of the major adverse extent of LGE (odds ratio (OR) 3.4 p=0.038 and p value <0.001 Respectively)

Conclusions: Within our population of HCM patients, the extent of LGE and the presence of an apical aneurysm identified by cardiac MRI were both significant predictors of major adverse clinical events.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are